Summary
Johnson & Johnson (JNJ) filed an amendment to its Current Report on Form 8-K on August 28, 2017, primarily to provide crucial financial details regarding its previously completed acquisition of Actelion Ltd. The acquisition, which closed on June 15, 2017, through JNJ's subsidiary Janssen Holding GmbH, was an all-cash tender offer. This amendment includes the audited consolidated financial statements of Actelion for the fiscal year ended December 31, 2016, prepared in accordance with U.S. GAAP. Additionally, it presents unaudited pro forma condensed combined financial information for Johnson & Johnson, reflecting the impact of the Actelion acquisition as of and for the three months ended April 2, 2017, and for the year ended January 1, 2017. Investors should note that this filing provides the necessary financial data to assess the immediate financial implications of the Actelion acquisition. The inclusion of Actelion's 2016 financials and the pro forma combined statements allows for a more informed evaluation of how the acquisition is expected to impact JNJ's financial position and performance going forward. This is particularly important for understanding the scale and financial integration of Actelion into Johnson & Johnson's operations.
Key Highlights
- 1Amendment to 8-K filing provides crucial financial information related to the Actelion acquisition.
- 2Acquisition of Actelion Ltd. was completed on June 15, 2017, via an all-cash tender offer by JNJ subsidiary Janssen Holding GmbH.
- 3Includes audited consolidated financial statements of Actelion Ltd. for the year ended December 31, 2016 (U.S. GAAP).
- 4Presents unaudited pro forma condensed combined financial information for Johnson & Johnson, reflecting the Actelion acquisition.
- 5Pro forma information covers periods ending April 2, 2017 (three months) and January 1, 2017 (full year).
- 6The filing aims to give investors a clearer financial picture post-acquisition.
- 7Exhibit 23 includes the consent of the independent auditor.